Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma. In a small study, all 12 patients responded, with manageable side effects. This combination may help advanced cases, according to the study investigators. Dr. Tomasson highlights ongoing research into bispecific antibodies, chimeric antigen receptor T-cell therapy, and the path toward a cure for patients with multiple myeloma.
Dr. Tomasson Reports Early Data from MagentisMM-20
By Michael H. Tomasson, MD - Last Updated: February 18, 2025Related Posts
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Linvoseltamab drives deep, durable responses in relapsed/refractory multiple myeloma, even in high-risk patients.
Phase III MIDAS trial challenges ASCT’s role in MM, showing extended Isa-KRd may rival transplant in MRD-negative patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.